Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489216 · ClinicalTrials.gov registry record · NA
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids
A NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT00489216 is a NA study that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT00489216, a NA study, was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Efalizumab may be an effective treatment for graft-versus-host disease of the skin caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying the side effects and how well efalizumab works in treating patients with graft-versus-host disease of the skin that did not respond to previous steroids.
Interventions
- BIOLOGICAL efalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00489216
The ClinicalTrials.gov registry entry for NCT00489216 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which efalizumab is the first listed.
NCT00489216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00489216 about?
NCT00489216 is a clinical study titled "Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids". RATIONALE: Efalizumab may be an effective treatment for graft-versus-host disease of the skin caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying the side effects and how well efalizumab works in treating patients with graft-versus-host disease of the skin that did not ...
What is the current status of trial NCT00489216?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2006-12. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00489216?
The interventions under investigation include: efalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00489216?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.